Safety and tolerability of extended-release niacin with laropiprant

被引：10

作者：

Yadav, Rahul ^{[2
]}

Kwok, See ^{[2
]}

Ammori, Basil J.

Issa, Basil ^{[3
]}

Soran, Handrean ^{[1
]}

机构：

[1] Cent Manchester Univ Hosp Fdn Trust, Univ Dept Med, Manchester, Lancs, England

[2] Univ Manchester, Sch Biomed, Cardiovasc Res Grp, Core Technol Facil, Manchester M13 9NT, Lancs, England

[3] Univ Hosp S Manchester NHS Fdn Trust, Dept Diabet & Endocrinologist, Manchester M23 9LT, Lancs, England

来源：

EXPERT OPINION ON DRUG SAFETY | 2012年 / 11卷 / 01期

基金：

英国惠康基金;

关键词：

hyperlipidemia; laropiprant; niacin; safety; tolerability; tredaptive; HIGH-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; NICOTINIC-ACID; PROSTAGLANDIN D-2; PRIMARY HYPERCHOLESTEROLEMIA; CHOLESTEROL LEVELS; SERUM-CHOLESTEROL; RECEPTOR; EFFICACY;

D O I：

10.1517/14740338.2011.638281

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited because of excessive flushing. Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. Therefore, it is time to collate available information to assess the safety and tolerability of combining niacin with LRP. Areas covered: The authors searched PubMed and MEDLINE for literature published between January 2006 and July 2011, for safety and tolerability reports of extended-release niacin (ERN) with LRP. Expert opinion: The addition of LRP to ERN, by reducing the side effect 'flushing', may enable lipidologists and physicians to use niacin more widely as part of lipid modification therapy, especially since the combination can be safely added to statins. However, it has to be accepted that the addition of LRP does not completely abolish flushing. The favorable safety profile supports the use of LRP to achieve higher therapeutic dosing of niacin.

引用

页码：151 / 159

页数：9

共 69 条

[1] Identification of scavenger receptor SR-BI as a high density lipoprotein receptor [J].

Acton, S ;

Rigotti, A ;

Landschulz, KT ;

Xu, SZ ;

Hobbs, HH ;

Krieger, M .

SCIENCE, 1996, 271 (5248) :518-520

[2]

[Anonymous], 2007, HYPERLIPIDAEMIA DIAG

[3]

[Anonymous], NIH STOPS CLIN TRIAL

[4]

Bays Harold E, 2003, Prev Cardiol, V6, P179, DOI 10.1111/j.1520-037X.2003.03142.x

[5] Comparison of once-daily, niacin extended/release/lovastatin with standard doses of atorvastatin and simvastafin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]) [J].

Bays, HE ;

Dujovne, CA ;

McGovern, ME ;

White, TE ;

Kashyap, ML ;

Hutcheson, AG ;

Crouse, JR .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (06) :667-672

[6] GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing [J].

Benyó, Z ;

Gille, A ;

Kero, J ;

Csiky, M ;

Suchánková, MC ;

Nüsing, RM ;

Moers, A ;

Pfeffer, K ;

Offermanns, S .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3634-3640

[7] Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells [J].

Benyo, Zoltan ;

Gille, Andreas ;

Bennett, Clare L. ;

Clausen, Bjoern E. ;

Offermanns, Stefan .

MOLECULAR PHARMACOLOGY, 2006, 70 (06) :1844-1849

[8] Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials [J].

Birjmohun, RS ;

Hutten, BA ;

Kastelein, JJP ;

Stroes, ESG .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :185-197

[9]

Birjmohun RS, 2004, NETH J MED, V62, P229

[10] Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].

Brown, BG ;

Zhao, XQ ;

Chait, A ;

Fisher, LD ;

Cheung, MC ;

Morse, JS ;

Dowdy, AA ;

Marino, EK ;

Bolson, EL ;

Alaupovic, P ;

Frohlich, J ;

Albers, JJ ;

Serafini, L ;

Huss-Frechette, E ;

Wang, S ;

DeAngelis, D ;

Dodek, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592

← 1 2 3 4 5 6 7 →